Business Context and Reporting Period
This Form 8-K Current Report, dated August 1, 2025, covers events occurring on July 31, 2025, for Silexion Therapeutics Corp, a Cayman Islands-based emerging growth company. The filing details the entry into a material definitive agreement involving a warrant inducement transaction to raise capital.
Key Financial Metrics and Transaction Details
The filing does not provide standard financial statements (revenue, profit, cash flow, or margins) as it is a current report on a specific transaction. Key financial terms of the transaction include:
- Expected Gross Proceeds: Approximately $1.8 million from the exercise of existing warrants.
- Existing Warrants Exercised: 152,106 warrants at a reduced exercise price of $11.57 per share.
- New Warrants Issued: Up to 304,212 new warrants at an exercise price of $11.32 per share.
- Placement Agent Fees: 7.0% cash fee plus 1.0% management fee on gross proceeds; additional fees apply upon exercise of new warrants.
- Placement Agent Warrants: 10,647 warrants issued to the agent at an exercise price of $14.4625 per share.
- Use of Proceeds: General corporate purposes.
Material Changes and Transaction Structure
The Company entered into an inducement offer letter with holders of 152,106 existing warrants (comprising Public Offering Warrants and Prior Inducement Warrants). Key structural changes include:
- Price Reduction: The exercise price for existing warrants was reduced from $20.25 and $22.50 to $11.57 per share.
- Share Split Adjustment: All warrant numbers and prices reflect a 1-for-15 reverse share split effected on July 29, 2025.
- Capital Increase Requirement: The transaction is contingent upon shareholder approval of an increase in authorized share capital at an extraordinary general meeting scheduled for August 12, 2025.
- Lock-up Provisions: The Company agreed not to issue ordinary shares or equivalents for 15 days following the closing date (through August 16, 2025) and not to effect Variable Rate Transactions for one year.
Outlook, Risks, and Contingencies
Management expects the transaction to close on or about August 1, 2025, subject to customary conditions. The filing highlights several risks and contingencies:
- Closing Contingency: The transaction may not close if conditions are not satisfied.
- Liquidity Risk: There is no established trading market for the New Warrants, and the Company does not intend to list them, resulting in extremely limited liquidity.
- Registration Timeline: The Company must file a resale registration statement within 30 days and seek effectiveness within 60 to 90 days.
- Forward-Looking Statements: The report contains forward-looking statements regarding the closing date and use of proceeds, which are not guaranteed.
Investor Verification Checklist
- Verify the outcome of the extraordinary general meeting on August 12, 2025, regarding the authorized share capital increase.
- Confirm the actual closing date and net proceeds received after deducting placement agent fees and expenses.
- Monitor the effectiveness of the Form S-3 resale registration statement for the New Warrant Shares.
- Review the impact of the 1-for-15 reverse share split on historical financial data and share counts.
- Assess the dilution impact of the 304,212 new warrants and 10,647 placement agent warrants.